Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

38.41
-0.8400-2.14%
Volume:441.94K
Turnover:17.08M
Market Cap:44.75B
PE:64.02
High:39.03
Open:39.01
Low:38.34
Close:39.25
52wk High:39.49
52wk Low:18.21
Shares:1.17B
Float Shares:1.09B
Volume Ratio:2.41
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.77
PE(LYR):31.74

Loading ...

Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus

MT Newswires Live
·
Jul 09

Teva, Polpharma Biologics announce global licensing agreement

TIPRANKS
·
Jul 09

Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada

MT Newswires Live
·
Jul 09

Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ

TIPRANKS
·
Jul 09

Movement Alert|Teva Pharmaceutical Industries Falls 5.17% in Regular Trading, Trading at $32.86

Market Focus
·
Jul 08

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Jul 08

Teva to advance TEV-‘408 into Phase 2b study in vitiligo in Q4

TIPRANKS
·
Jul 07

Teva - Tev-’408 Shows Improved Skin Pigmentation and no Safety Signals in Phase 1B

THOMSON REUTERS
·
Jul 07

Teva call volume above normal and directionally bullish

TIPRANKS
·
Jul 07

Teva call volume above normal and directionally bullish

TIPRANKS
·
Jul 02

Lowe’s, Kraft Heinz, Teva, Take-Two, HIVE Insider Shock

TIPRANKS
·
Jun 27

Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback

Simply Wall St.
·
Jun 22

FDA Seeks Updated Labeling for Testosterone Therapies

MT Newswires Live
·
Jun 19

Teva Submits New Drug Application for Ecopipam to Treat Pediatric Tourette Syndrome

MT Newswires Live
·
Jun 19

Teva submits NDA for Ecopipam to FDA

TIPRANKS
·
Jun 19

Teva Releases Q2 2026 Aide Memoire

THOMSON REUTERS
·
Jun 19

Teva - Ecopipam Showed Statistically Significant Benefit on Primary Efficacy Endpoint in Pediatric Patients

THOMSON REUTERS
·
Jun 19

Jefferies continues to like Teva after recent pullback

TIPRANKS
·
Jun 19

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 15

How Investors Are Reacting To Teva (TEVA) AUSTEDO Real‑World Data On Tardive Dyskinesia Improvement

Simply Wall St.
·
Jun 11